Baseline Patient Risk Profile
Three factors raise baseline pancreatitis risk before any drug is started.
- 3: Risk factors screened (history, gallstones, triglycerides)
- ~15%: Gallstone prevalence (T2D) (higher in obesity)
- ≥500 mg/dL: Triglyceride risk cutoff (severe hypertriglyceridemia)
- ~20–30%: Prior pancreatitis recurrence (general population estimate)
History of pancreatitis
Prior acute or chronic pancreatitis raises baseline recurrence risk.
Gallstone disease
Gallstones are the leading cause of acute pancreatitis overall.
Hypertriglyceridemia
Very high triglycerides independently trigger pancreatic inflammation.
GLP-1 Therapy Initiated
Drug-associated risk combines with existing baseline risk factors.
- ~0.2–0.3%: Reported incidence (across GLP-1 trial pools)
- Small: Absolute risk increase (vs. placebo in meta-analyses)
- Additive: Risk-factor multiplier (each factor raises baseline)
- Yes: Monitoring recommended (for risk-positive patients)
Drug-associated signal
Large trials show a small, inconsistent pancreatitis signal.
Combined risk model
Baseline factors plus drug exposure define total risk.
Patient selection
Risk-positive patients warrant closer clinical follow-up.
Warning Symptoms to Monitor
Persistent severe abdominal pain radiating to the back is the key sign.
- Epigastric pain: Hallmark symptom (radiates to back)
- Nausea / vomiting: Associated symptoms (common accompaniment)
- Sudden, persistent: Onset pattern (not intermittent cramping)
- >48 hours: Duration flag (warrants urgent evaluation)
Pain character
Severe, steady epigastric pain radiating posteriorly is classic.
Accompanying signs
Nausea, vomiting, and tenderness often occur together.
Patient education
Patients are told to report symptoms immediately, not wait.
Decision Point — Test and Hold
Symptom presence triggers lipase/amylase testing and possible drug hold.
- >3× ULN: Lipase threshold (supports diagnosis)
- >3× ULN: Amylase threshold (secondary marker)
- CT / ultrasound: Imaging option (confirms diagnosis, rules out stones)
- Hold therapy: Drug action (pending workup results)
Lab testing
Lipase and amylase confirm or rule out pancreatic inflammation.
Drug hold decision
Therapy is paused while results and symptoms are evaluated.
Escalation path
Confirmed cases move to imaging and specialist referral.
Outcome — Rare Event, Managed Early
Most patients never develop pancreatitis; early action limits severity.
- Low: Overall absolute risk (rare across GLP-1 users)
- Prevents progression: Early recognition benefit (to severe disease)
- Rare: Severe case rate (with prompt monitoring)
- Usually resolves: Post-discontinuation course (after drug hold)
Population-level risk
Absolute risk stays low even with risk factors present.
Value of monitoring
Symptom awareness catches cases before severe progression.
Ongoing care
Risk-positive patients continue closer routine surveillance.
Most patients on GLP-1 therapy never develop pancreatitis.